HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Watanabe, N. Articles by Seto, H. Search for Related Content PubMed PubMed Citation Articles by Watanabe, N. Articles by Seto, H.

The Radiotoxicity of ¹³¹I Therapy of Thyroid Cancer: Assessment by Micronucleus Assay of B Lymphocytes

¹ Department of Radiology, Toyama Medical and Pharmaceutical University, Toyama, Japan
² Department of Pediatrics, Toyama Medical and Pharmaceutical University, Toyama, Japan
³ Department of Nuclear Medicine, Kanazawa University, Kanazawa, Japan
⁴ Department of Radiology, Asahikawa Medical University, Asahikawa, Japan
⁵ Department of Clinical Infectious Diseases, Toyama Medical and Pharmaceutical University, Toyama, Japan

ABSTRACT

We investigated cytologic radiation damage in thyroid cancer after ¹³¹I therapy using micronucleus assay (MNA) of B lymphocytes exclusively, as opposed to our previous study in which MNA of all lymphocyte subsets was used. Methods: We studied 22 thyroid cancer patients treated with 3.7 GBq of ¹³¹I. Peripheral lymphocytes were harvested, and B lymphocytes were isolated by an immunomagnetic method and assayed for the frequency of micronuclei. Results: The frequency of micronuclei among B cells after ¹³¹I therapy was significantly increased relative to that in untreated control subjects, and the ¹³¹I-induced increase in micronuclei frequency among B cells was significantly greater than that among all lymphocytes. Conclusion: Compared with the MNA of all lymphocytes, the MNA among specifically B cells may more sensitively detect cytologic radiation damage associated with ¹³¹I therapy of thyroid cancer.

Key Words: micronucleus assay • thyroid cancer • radioiodine therapy • radiotoxicity • B lymphocytes

This article has been cited by other articles:

				A. Serna, M. Alcaraz, J. L. Navarro, C. Acevedo, V. Vicente, and M. Canteras Biological dosimetry and Bayesian analysis of chromosomal damage in thyroid cancer patients Radiat Prot Dosimetry, May 1, 2008; 129(4): 372 - 380. [Abstract] [Full Text] [PDF]

				H. Hanscheid, M. Lassmann, M. Luster, S. R. Thomas, F. Pacini, C. Ceccarelli, P. W. Ladenson, R. L. Wahl, M. Schlumberger, M. Ricard, et al. Iodine Biokinetics and Dosimetry in Radioiodine Therapy of Thyroid Cancer: Procedures and Results of a Prospective International Controlled Study of Ablation After rhTSH or Hormone Withdrawal J. Nucl. Med., April 1, 2006; 47(4): 648 - 654. [Abstract] [Full Text] [PDF]

				M. Lassmann, M. Luster, H. Hanscheid, and C. Reiners Blood Dosimetry and Dose-Rate Effects After Radioiodine Therapy of Differentiated Thyroid Cancer J. Nucl. Med., May 1, 2005; 46(5): 899 - 899. [Full Text] [PDF]